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Ecteinascidin-743 (ET-743) is a tetrahydroisoquinoline alkaloid iso-
lated from the tunicate Ecteinascidia turbinata currently under phase
II clinical trials for its potent anticancer activity. ET-743 binds DNA in
the minor groove and forms covalent adducts with some sequence
specificity. It selectively inhibits in vitro binding of the CCAAT box
factor NF-Y. In this study, we assayed ET-743 function in vivo on the
HSP70 promoter. On heat induction, the drug blocks transcription
rapidly at pharmacological concentrations and in a CCAAT-dependent
manner, whereas the activity of the CCAAT-less simian virus 40
promoter is not affected. The effect is exerted at the mRNA level. The
distamycin-like alkylating tallimustine is inactive in these assays.
Binding of NF-Y and of the heat-shock factor is normal in ET-743-
treated cells. Run-on analysis of several endogenous genes further
proves that the drug has rapid, profound, and selective negative
effects on transcription. Thus, this marine-derived compound is a
promoter-specific, transcription-interfering agent.
drug u DNA binding u transcription
Ecteinascidin-743 (ET-743) is a marine tetrahydroisoquinolinealkaloid isolated from the tunicate Ecteinascidia turbinata with
a potent cytotoxic activity against a variety of tumor cell lines in vitro
and against several rodent tumors and human tumor xenografts in
vivo (1). ET-743 is under phase II clinical investigation in Europe
and the U.S. as a potential anticancer drug (2, 3). Its primary mode
of action is poorly understood. ET-743 binds to the minor groove
of DNA with some degree of sequence specificity (4), forming
covalent adducts by reacting with the N-2 of guanine to its carbi-
nolamine moiety (refs. 5–7; reviewed in ref. 8). At high concentra-
tions, ET-743 (and the related synthetic drug phthalascidin) targets
DNA topoisomerase I in vivo (9, 10).
In theory, all DNA-binding drugs could interfere with
crucial cellular functions, such as DNA repair, replication, and
transcription (8). Transcription is regulated by promoter and
enhancer elements recognized by gene-specific DNA-binding
proteins, by general transcription factors, and, at a higher level,
by chromatin structures (11). Impairment of the complex
interactions between activators and their DNA targets could
lead to a change in the pattern of gene expression. Interference
at this level by alkylating drugs might help explain their
profound biological functions. Minor groove binders, such as
the distamycins and CC-1065, have a high affinity for AT-rich
DNA sequences and were reported to inhibit DNA binding of
sequence-specific factors involved in transcriptional activation
(12–19). We initially tested whether ET-743 was able to inhibit
the binding of several known transcription factors (19); most
of them were not inhibited, even at very high concentrations,
up to 300 mM. Only SRFyTCF and NF-Y showed some level
of sensitivity to the drug, albeit at suprapharmacologic con-
centrations. Interestingly, preincubation of ET-743 with NF-Y
yielded inhibition of DNA binding at lower concentrations
compared with preincubating the drug with DNA, suggesting
that the protein rather than the CCAAT box is a target.
Several considerations have since led us to focus our atten-
tion on NF-Y. NF-Y activates the CCAAT element, present in
25% of eukaryotic promoters (20), including many regulated
during the cell cycle (21). NF-Y is composed of three different
subunits, NF-YA, NF-YB, and NF-YC, all of which are
necessary for DNA binding. NF-YB and NF-YC are related to
core histones, sharing a histone fold motif. NF-YB–NF-YC
dimerization is a prerequisite for NF-YA association and
subsequent DNA binding. Methylation interference and IC-
substitution mutations on the target CCAAT sequence suggest
that NF-Y makes important contacts in the minor groove (17).
Two unrelated cytotoxic drugs (i.e., genistein and HMN-154)
inhibit in vitro binding of NF-Y to the CCAAT box by targeting
the NF-YB subunit (22, 23). Whether their antiproliferative
effects are related to inhibition of NF-Y activity remains to be
elucidated. Finally, ET-743 is produced by a marine tunicate,
presumably as an antifeedant or antimicrobial agent for pro-
tection in its natural environment. NF-Y proteins are among
the most conserved throughout evolution and are found in
distantly related phyla: vertebrates, invertebrates, plants,
fungi, and parasites. In fungi, for example, deletion of NF-Y
genes causes a phenotype of slow growth (24). For the above
reasons, we decided to set up an in vivo approach to understand
whether NF-Y-mediated transcriptional activation is a possible
pharmacological target of ET-743.
Materials and Methods
Drugs and Cell Culture. ET-743, ET-14, and tallimustine were
prepared as a 1-mgyml stock solution dissolved in ethanol and
kept at 220°C. Before use, the drugs were diluted freshly in
double-distilled sterile water to the desired concentrations.
Mouse NIH 3T3 fibroblasts were maintained in DMEM sup-
plemented with 10% (volyvol) FCS. Cells were cotransfected
with 10 mg of HSP70, HSP70Ym, chloramphenicol acetyltrans-
ferase (CAT; a kind gift of N. Landsberger, University of
Insubria, Varese, Italy), or the simian virus 40-containing NbGal
plasmids and 2 mg of a plasmid containing the hygromycin-
resistance gene. For extract preparation, cells were washed in
PBS, resuspended in 100 mM TriszHCl (pH 7.8), sonicated, and
controlled for protein concentrations by the Bradford reagent
(Sigma). CAT assays were carried out with equivalent amounts
of extracts by the quantitative method described in ref. 25.
b-Galactosidase activity was measured in 60 mM Na2HPO4, 40
mM NaH2PO4, 1 mM MgCl2, 50 mM b-ME, and 0.66 mgyml
O-nitrophenyl b-D-galactopyranoside. The reaction was stopped
by adding 1 M Na2CO3, and the A420 was measured. Results from
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four to six independent experiments were plotted; standard
deviations were ,20%.
Electrophoretic Mobility-Shift Assay. Nuclear extracts were prepared
according to the method described in ref. 26. Electrophoretic
mobility-shift assays were performed as described in refs. 18 and 19.
Nuclear extracts (4 mg) were incubated for 15 min at room
temperature in the presence of 300 ng of poly(dI-dC) with the Y box
oligonucleotide or with an oligonucleotide containing the Xenopus
HSP70 proximal heat-shock element (HSE; 59-ACGAAATG-
GAAGCCTCGGGAAACTTCGGGTCGG).
Run-On Assays. Run-on transcription on isolated NIH 3T3 nuclei
was performed by treating cells with 30 nM of ET-743 for 2 and
4 h. Isolation of nuclei from cells, in vitro labeling of nascent
mRNA with [a-32P]UTP, and isolation of mRNA were carried
out according to the methods described in ref. 27. Plasmids (5
mg) containing the indicated cDNAs were spotted onto nitro-
cellulose, which was then hybridized with labeled RNAs and
washed as described (27). Autoradiographs of the filters were
quantified by densitometry with a Molecular Dynamics Laser
Densitometer and IMAGEQUANT software.
Results
Transcriptional Interference Effect of ET-743 on the Transfected HSP70
Promoter. The structure of ET-743 is shown in Fig. 1. We chose the
Xenopus HSP70 promoter for the following reasons: (i) it has few
important elements, consisting of three HSEs binding to the
heat-shock factor (HSF; refs. 28 and 29) and two CCAAT boxes
activated by NF-Y (30, 31); (ii) it is a very efficient and rapidly
inducible promoter, enabling evaluation of a direct role of the drug
in activation; and (iii) information about the role of NF-Y in
chromatin configuration and interactions with coactivators is avail-
able (30, 31). We cotransfected mouse NIH 3T3 fibroblasts with
constructs containing a reporter CAT gene driven either by a
wild-type HSP70 promoter or by a promoter mutated in the two
CCAAT boxes (see Fig. 2 A and B), together with a vector
containing the hygromycin-resistance gene. A pool of more than
100 clones was selected as well as several individual clones. The
3T3-HSP70 and 3T3-HSP70Ym cells were grown and induced at
42°C for 2 h to verify the function and inducibility on heat treatment
of the integrated CAT genes. The 3T3-HSP70 cells, but not
3T3-HSP70Ym cells, showed a 10- to 15-fold induction of CAT
activity (see below). We therefore tested ET-743 in this system.
First, we incubated increasing concentrations of ET-743 with
Fig. 1. Structures of Et-743 and tallimustine.
Fig. 2. Inhibition of Xenopus HSP70 promoter activity by ET-743. (A Top) The
scheme depicts the Xenopus HSP70 promoter used to obtain stable cell lines (28).
(A Middle) Dose response of ET-743 on the 3T3-HSP70 pool; black bars are CAT
activities in noninduced cells; gray bars represent CAT activities after heat induc-
tion. ET-743 was added to exponentially growing cells 2 h before the 2-h shock at
42°C;cellswerethenplacedfor2hat37°Ctorecover.Valuesarecalculatedasfold
of activation over basal, non-heat-shocked conditions. (A Bottom) Northern blot
analysis of CAT mRNA of 3T3-HSP70 cells extracted from untreated cells kept at
37°C (lane 1) and at 1 h after heat induction either without (lane 2) or with
pretreatments for 2 h with the indicated concentrations of ET-743 (lanes 3–5). (B)
Same conditions as described for A, except that the 3T3-HSP70Ym pool was used.
(C) Dose response of ET-743 from experiments similar to the ones described for A
and B, except that three individual clones of HSP70 were used. (D) Comparison
between the inhibitory curves of ET-743 on the 3T3-HSP70 pool. Cells were
pretreated for 2 h as described for A (2h), pretreated for 1 min and then placed
at 42°C (I), or trypsinized before adding ET-743 and then immediately (within 1
min) placed at 42°C (T).











3T3-HSP70 or 3T3-HSP70Ym for 2 h at 37°C, followed by a heat
shock of 2 h at 42°C and subsequent recovery at 37°C. Cells were
then harvested, and CAT activity was measured. A clear dose-
dependent negative effect of ET-743 was evident with 3T3-HSP70
already at 10 nM concentration (Fig. 2A); Northern blot analysis
indicated that the effect is indeed at the level of mRNA (Fig. 2A).
With 3T3-HSP70Ym cells, only a small level of induction was
observed, consistent with previous results (30, 31); essentially, this
level was unaffected by ET-743 treatment (Fig. 2B). We then
performed this type of experiment with three individual clones of
3T3-HSP70. Results were similar to those of the pooled cells, but
the ET-743 concentrations required to inhibit activity were some-
what more variable among individual clones (Fig. 2C). Clones 1 and
3 were inhibited significantly at 3 nM, whereas clone 4 required 30
nM. On individual clones of 3T3-HSP70Ym, no effect of the drug
was observed (not shown). These results suggest that the site or sites
of integration play some role in ET-743 sensitivity. Induction of the
HSP70 promoter is known to be very rapid and is already detectable
after 2 min (28, 29). To verify the rapidity of the ET-743 inhibitory
response, we modified the experimental conditions, eliminating the
2-h preincubation period and adding the drug immediately before
placing plates at 42°C either to cells attached to the plastic (Fig. 2D,
see I) or to trypsinized cells (Fig. 2D, see T). The former protocol
required a 100-nM dose, whereas the latter showed little difference
in the inhibition profile compared with the 2-h pretreatment (Fig.
2D, 2h). Thus, the effect of the drug is clearly dose-dependent,
exerted at the level of mRNA production, and visible within
minutes from addition.
Specificity of the ET-743 Effect. To verify the specificity of the drug
for the HSP70 promoter, we selected a pool of NIH 3T3 cells in
which the CCAAT-less simian virus 40 promoter-enhancer driving
a b-galactosidase reporter gene was stably introduced. After stan-
dard treatments, we observed that the simian virus 40 transcription
unit was not affected by the presence or absence of ET-743, either
at 37°C or after a 42°C shock, determining that the negative effect
of the drug could not be unmasked under these conditions (Fig.
3A). Next, we used the cytotoxic agent tallimustine on 3T3-HSP70
cells; tallimustine shares some features in common with ET-743,
including the capacity to bind in the minor groove, to alkylate DNA
(32), and to inhibit NF-Y binding (17). Results of these experiments
are shown in Fig. 3B; neither basal nor heat-induced transcription
of the 3T3-HSP70 pool is influenced significantly, even at a high
cytotoxic drug concentration (30 mM). An ET-743 analog, ET-14,
also showed no inhibition of heat-mediated transcriptional activa-
tion (not shown). Taken together, these data strongly indicate that
the ET-743 effect does not occur by virtue of widespread Pol II
inhibition. This effect is different from that seen with another minor
groove binder, which is inactive in transcriptional interference.
Function of DNA-Binding Activators of HSP70 Transcription in ET-743-
Treated Cells. A possible explanation for the lack of HSP70
induction is that the drug negatively affects NF-Y-or HSF-
binding capacity (28–31). In particular, HSF is known to exist in
non-DNA-binding monomeric forms, and only after increasing
the temperature, are trimerization and efficient DNA binding
achieved. The previous results thus could be explained by
assuming that ET-743 inhibits HSF trimerization andyor HSE
binding. After a 2-h incubation with increasing ET-743 concen-
trations, NIH 3T3 cell lines were shocked for 1 h, after which
nuclear extracts were prepared. As expected, HSF binding was
Fig. 3. Specificity of the ET-743-HSP70 effect. (A) A pool of 3T3-simian virus
40 cells were treated with the indicated amounts of ET-743 for 2 h and then
either kept at 37°C or heat treated at 42°C. Extracts were prepared after 2 h
and assayed for b-galactosidase activity (23). Results are plotted as percentage
of untreated cells. Gray bars, 37°C; black bars, 42°C heat shock. (B) Dose
response of tallimustine on the 3T3-HSP70 pool; the indicated amounts of the
drug were added 2 h before the heat treatment. Gray bars, 37°C; black bars,
activities after heat shock.
Fig. 4. DNA-binding activities of HSP70 activators in ET-743-treated cells.
Extracts were prepared according to the protocol outlined (Top; ref. 26).
Nuclear extracts were assayed in the electrophoretic mobility-shift assays with
HSE and Y box probes (Middle), and the corresponding CAT activities in the
cytoplasmic extracts are shown (Bottom). Even lanes are extracts from heat-
shocked cells; uneven lanes are extracts from cells kept at 37°C.
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present only in heat-shocked extracts (Fig. 4, lanes 1 and 2),
increasing 5-fold in ET-743-treated cells in a dose-dependent
manner and reaching a maximum at 100 nM (Fig. 4, compare
lanes 2 with 4, 6, 8, and 10). NF-Y-binding activity was un-
changed, whether the cells were heat-shocked (Fig. 4, lanes 2, 4,
6, 8, and 10) or kept at 37°C (Fig. 4, lanes 1, 3, 5, 7, and 9). The
corresponding promoter activity showed the usual inhibition of
heat-shock induction, even after only a 1-h incubation at 42°C
and in the absence of a 2-h recovery period (Fig. 4 Bottom).
These results rule out negative effects on HSF trimerization and
suggest that lack of DNA binding by the HSP70 activators NF-Y
and HSF might be not to be a contributing reason for ET-743
promoter inhibition.
Effects of ET-743 on Endogenous Genes. To ascertain whether ET-743
has direct transcriptional effects at pharmacological concentrations
on endogenous genes, we performed run-on analysis on isolated
NIH 3T3 nuclei. First, we analyzed the transcription rates of mouse
HSP70 under basal and induced conditions. A 2-h treatment at 30
nM concentration with ET-743 clearly inhibited gene activation and
had no effect on vimentin (Fig. 5A). Next, we decided to extend
these observations to other endogenous genes. Fig. 5B shows that
short 2- and 4-h treatments induce differential effects on the
transcriptional activity of various promoters. Glyceraldehyde-3-
phosphate dehydrogenase and vimentin are essentially unchanged;
MDR1 and E2F1 are somewhat inhibited, and the rates of c-jun, of
histone H2B, of histone H4, all of which contain functionally
important CCAAT-boxes, and of c-fos, a CCAAT-less promoter,
are affected severely, by 3- to 7-fold. Overall, these in vivo data fully
support the hypothesis that ET-743 is not a general Pol II inhibitor
but rather has profound, primary, and specific negative effects on
gene expression.
Discussion
We approached the problem of finding the mechanism or mech-
anisms of action of the cytotoxic agent ET-743. From our original
in vitro observation of selective negative effects on some transcrip-
tion factors to the their DNA targets, we proceeded to investigate
the role of ET-743 in vivo. Our experiments on stable transfections
of the HSP70 promoter strongly suggest that ET-743 has a specific
negative effect on transcription, which is not shared by another
minor groove binder alkylating DNA, and that for this activity, the
CCAAT-box is required. Two observations strongly indicate that
the effect on transcription is primary: (i) the inhibition is extremely
rapid, because a 1-min preincubation is sufficient to observe a
significant degree of inhibition, and (ii) the effect is observed at
pharmacological concentrations. It should be noted that the doses
used in this study are within the range achieved in the plasma of
patients undergoing clinical trials. To our knowledge, our study is
the first demonstration that a cytotoxic alkylating agent is active at
this level. Many anticancer drugs seem to influence gene expression
by acting on specific promoters: cisplatin on cyclin A, doxorubicin
on Id2A, taxol on IL-8, and genistein on GRP78 and HSP70
(33–36). It should be noted, however, that the conditions used in
these studies involved long incubation times (24–36 h) at drug
concentrations in the high micromolar range, one to three orders of
magnitude higher than concentration levels showing cytotoxic
effects. This proviso raises the possibility that transcriptional effects
might be secondary to impairment of other well known functions:
inhibition of microtubule depolymerization by taxol, of protein
tyrosine kinases by genistein, and of DNA synthesis by cisplatin, as
well as DNA topoisomerase II poisoning by doxorubicin (reviewed
in ref. 37).
A recent report by Takebayashi et al. (9) suggests that DNA
topoisomerase I is a molecular target of ET-743 in CEM cells at
high (10 mM) concentrations. A parallel study by Martinez et al. (10)
supports this finding with one caveat: because of the high concen-
tration levels (4 mM in A375 cells), poisoning of topoisomerase I is
very unlikely to be the primary effect of ET-743 or of the related
synthetic drug phthalascidin, especially because camptothecin-
resistant cells retain sensitivity to the two compounds. Our study
shows that induction of HSP70 and of some cellular genes is
prevented in vivo at concentrations two to three orders of magni-
tude lower, thus suggesting that poisoning of gene-specific activa-
tors is targeted. The two prominent actors in HSP70 are NF-Y and
HSF. The drug does not prevent formation of high-affinity HSF
trimers (Fig. 4); however, the possibility exists that a DNA-bound
HSF could be unable to activate, because uncoupling of the two
functions has been reported (38). In an accompanying paper, Scotto
and colleagues (39) describe a similar activity for ET-743 evaluated
in a different experimental system: cells are the colon carcinoma
SW620; the promoter is the NF-Y-dependent human MDR1; the
inducers are trichostatin A, UV irradiation, and butyrate; however,
the inhibitory concentrations are equally low (10–50 nM). Because
the HSP70 and MDR1 promoters have different architectures and
because the only obvious common feature is the presence of a
Fig. 5. Run-on analysis of endogenous genes. (A) Nuclear run-ons of un-
treated and heat-shocked NIH 3T3 nuclei. ET-743 (30 nM) was added 2 h before
the heat shock, and RNA was extracted after 1 h (27). Three probes were
spotted on the filter: vector control (Vect), vimentin (Vim), and HSP70. Quan-
titation is shown. (B) Same conditions as described for A, except that the
indicated cDNAs were analyzed at 37°C; NIH 3T3 cells were pretreated with 30
nM of ET-743 for 2 and 4 h before RNA run-on analysis. G3PDH, glyceralde-
hyde-3-phosphate dehydrogenase.











CCAAT box on which NF-Y acts (40), it is tempting to speculate
that NF-Y is one of the intended targets.
If, indeed, NF-Y is one of the targets, what might be the
mechanism or mechanisms? Several lines of reasoning suggest that
inhibition of DNA binding is most likely not the reason for the rapid
transcriptional inhibition. First, inhibition of NF-Y binding by
ET-743 in vitro is seen at very high doses (10 and 30 mM) and
actually at higher concentrations when the drug is preincubated
with the DNA than when it is incubated with NF-Y (19). Second,
nuclear extracts from cells treated in vivo yielded normal NF-Y and
actually increased HSF binding, ruling out a generalized negative
effect on HSP70 activators. Third, in vivo footprinting analysis of
mammalian HSP70 promoters proved that CCAAT boxes are
protected—that is, bound by NF-Y- even before heat induction (41,
42) and, indeed, a necessary condition for presetting an active
promoter (26). Therefore, we consider it unlikely that NF-Y, stably
bound to high-affinity CCAAT boxes, might be displaced rapidly by
the low concentrations of ET-743 used in this study. However, two
alternative, but not mutually exclusive models could be envisaged
to explain the molecular mechanisms of drug action. (i) The
apparent necessity for the C ring, which protrudes out from the
minor groove in the NMR drug-DNA adducts, suggests that ET-743
might not interfere with DNA binding per se but rather modify the
delicate network of neighboring interactions by binding to sites
close to transcriptional activators. In this regard, as a consequence
of drug binding, DNA is bent toward the minor groove (8). This
bending could well change the overall three-dimensional structure
of a promoter, and we note that indeed the capacity of NF-Y to
induce large directed bends is most likely important for its pro-
moter-organizing activities (43, 44). (ii) In the framework of the
many crucial protein–protein interactions known to be essential to
activate a given promoter, other levels could be involved that do not
depend on the DNA-binding activity of the drug with neighboring
activators, coactivators, or the Pol II holoenzyme. For consider-
ation, ET-743 might prevent association of histone acetylases that
are normally required for full promoter function. In this respect, we
note that, on HSP70, NF-Y recruits and is acetylated by CBP, a
coactivator with histone acetylase activity (26), and that, on MDR1,
NF-Y recruits PyCAF, another histone acetylase (40).
To explain the antiproliferative activity of ET-743, putative
targets might be cell-cycle-regulated promoters, many harboring
essential NF-Y sites: genes involved in DNA metabolism andyor
genes coding for cell-cycle regulators (21). Within the trimeric
complex, NF-YA is modulated during the cell cycle, leading to
variations in the CCAAT-binding activity (45). A crippled NF-Y
would probably hamper proper regulation of these promoters,
delaying transcription of crucial genes and affecting the timely
progression through the cell cycle. Interestingly, we have recently
obtained evidence that ET-743 causes a remarkable delay in S
phase progression of the cell cycle, eventually resulting in a
G2yM block (E. Erba, G.F., and M.D.’I., unpublished work).
Finally, it should be emphasized that NF-Y might just be one of
the possible transcription factors involved. Our in vitro DNA-
binding inhibition analysis of transcription factors also pointed to
SRF, an important activator of the c-fos gene, whose expression
is indeed inhibited in the run-on experiments described herein.
The assays developed in this study will allow testing of this
hypothesis with other promoters and transcriptional activators.
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